Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | HMGCR | P04035 | 5/20 | 0.77 |
| ▸ | RXRA | P19793 | 3/20 | 0.77 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273651 | 1.00 | NR4A2 (0.81) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL9031227 | 1.00 | NR4A2 (0.81) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14262699 | 1.00 | NR4A2 (0.81) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL13776435 | 0.92 | NR4A2 (0.81) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14569976 | 0.90 | NR4A2 (0.87) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL10049193 | 0.90 | NR4A2 (0.87) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14569977 | 0.90 | NR4A2 (0.87) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL12058587 | 0.90 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL10049191 | 0.90 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL3369 | 0.90 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692018-B2 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090176987-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7339062-B2 | Method for producing a 3,5-dihydroxy-6-heptenoate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-03-04 | — | — | US | disclosed |
| US-20070112024-A1 | Crystal form of quinoline compound and process for its production | OHARA ET AL, YOSHIO | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112024-A1 | Crystal form of quinoline compound and process for its production | VAT1, CACNA1A, VMP1 | NR4A2 4167/4885PDE4D 1126/4885NR1I2 3919/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | NR4A2 1528/4885PDE4D 1571/4885NR1I2 1518/4885 |
| US-20090176987-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | VAT1, CACNA1A, VMP1 | NR4A2 4167/4885PDE4D 1126/4885NR1I2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.